Table 2 Baseline characteristics of EV-positive patients grouped by their CCR5 genotype
CCR5del32 hetero- or homozygous (n = 20) | CCR5 wildtype (n = 77) | p-value | |
|---|---|---|---|
Clinical classification* | |||
EV persistence [n (%)] | 0 (0.0) | 23 (29.8) | 0.003 |
EV clearance [n (%)] | 20 (100.0) | 22 (28.5) | < 0.001 |
EV + IFN [n (%)] | 0 (0.0) | 32 (41.5) | < 0.001 |
Endpoint of death [n (%)]a | 0 (0.0) | 15 (19.48) | 0.036 |
Clinical baseline parameters# | |||
Age (years ± SD) | 49 ± 13 | 51 ± 14 | 0.541 |
Male [n (%)] | 14 (70.0) | 52 (67.5) | 0.831 |
NYHA I/II/III/IV (%) | 30/50/10/10 | 10/52/36/2 | 0.237 |
EF at baseline (% ± SD) | 62 ± 12 | 48 ± 19 | 0.006 |
LVEDD (mm ± SD) | 51 ± 9 | 57 ± 10 | 0.022 |
LVEDS (mm ± SD) | 41 ± 13 | 44 ± 12 | 0.387 |
Palpitations (%) | 66.7 | 50.1 | 0.390 |
Arrhythmias (%) | 42.9 | 36.4 | 0.747 |
AVB (%) | 0.0 | 10.4 | 0.348 |
RBBB (%) | 12.5 | 4.3 | 0.352 |
LBBB (%) | 25.0 | 12.8 | 0.374 |
Syncopies (%) | 11.1 | 9.4 | 0.878 |
Diabetes (%) | 20.0 | 15.5 | 0.727 |
Glycosides (%) | 25.0 | 21.2 | 0.776 |
Diuretics (%) | 62.5 | 63.9 | 0.920 |
Β-blocker (%) | 53.8 | 66.0 | 0.630 |
ACE (%) | 50.0 | 76.0 | 0.077 |
Cumarin (%) | 8.3 | 22.0 | 0.667 |
Antiarrhythmics (%) | 0.0 | 18.8 | 0.193 |
Pacemaker/ICD (%) | 0.0/0.0 | 6.1/2.0 | 0.425 |